Tissue Regenix Share Discussion Threads

[luminoso] 25/11/2015 13:00

The spread is misleading. Buying is happening at less than quoted mid price. I am always tempted to have a few under 15p.

[luminoso] 25/11/2015 11:25

Had a great effect on the share price ! I can feel a top up coming on, but might wait to see if there is more to this fall than meets the eye currently.

[luminoso] 25/11/2015 10:51

Just received this from Edison - webcast interview with Odell



Nothing new but concise summary.

[ali47fish] 25/11/2015 09:08

this is down again

[rayrac] 19/11/2015 09:15

It appears the mms are trying to awaken some interest here....or there's some underhand selling we can't see?😎

[rayrac] 17/11/2015 17:05

Well, turnover would help!

[igbertsponk] 17/11/2015 14:57

TO I assumed turnover. Once that ramps up and proves the commercial viability then the price will begin to motor again. Time for the salesmen to start selling !

[rayrac] 17/11/2015 14:51

P for profit...I think and, T/O for takeover!

[ali47fish] 17/11/2015 14:05

i dont know what the p or the T O is ?

[rayrac] 17/11/2015 08:49

Haven't looked here for a while. I'm not alone in that I suspect?

The p word doesn't bother me, it's the T O word I'm interested in! Any sign of success and the big boys will be here.

[bamboo2] 05/11/2015 20:26

sp, The P word is years away.

Doesn't stop management looking after their own interests though!

YORK, 5 November 2015 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Company"), the regenerative medical devices company, announces that it has today issued and allotted 444,508 ordinary shares of 0.5p each in the Company, following an exercise of options which were granted under the Company's unapproved share option scheme.

The 444,508 new ordinary shares will rank pari passu with the existing ordinary shares and application will be made for these new ordinary shares to be admitted to trading on AIM. It is expected that Admission will occur at 8:00 a.m. on 11 November 2015

[swiss paul] 05/11/2015 19:56

Aye - but no mention of the P word anywhere.

[bamboo2] 04/11/2015 10:19

11:26AM GMT 03 Nov 2015

Regenerative medical technology company Tissue Regenix Group is a prime example of what can be achieved when the worlds of academia and business come together. The company was spun out of research conducted at the University of Leeds, looking at the potential of decellurising biological materials from human or animal donor tissues, crucially leaving intact a receptive matrix for patients' own cells to build upon, regenerating healthy tissue in damaged or worn out areas of the body.

A pioneer in its industry, Tissue Regenix remains committed to ongoing research and improved patient outcomes, particularly within the areas of cardiac, wound care and sports medicine.

In the video, above, CEO Antony Odell and his team tell the Telegraph Business Club how the enterprise has grown from its intriguing, fledgling university research to become an international concern.


Company name: Tissue Regenix

Business sector: research and development in medical devices

Location: York, UK and San Antonio, Texas, USA

Turnover: £252,000 (from 1 February to 31 July 2015)

Number of employees: 47 UK-based staff, 20 US staff including sales staff

Year founded: 2006

[luminoso] 02/11/2015 08:58

Thanks, bamboo.

[bamboo2] 01/11/2015 10:19

Slides from CMD now viewable in a pdf.

[bamboo2] 28/10/2015 14:00

luminoso, cheers. Sp needs eod close above 20.75 to confirm a potential DB.

[luminoso] 27/10/2015 23:35

Second the comment from Ray.
Where do you see the double bottom forming, bamboo2 ? I can see the DB in April but not sure where the second bottom is forming currently.

[bamboo2] 27/10/2015 08:27

Ray, yes the share price looking a little happier.

Chartwise, could be setting up for a Double Bottom.

[rayrac] 26/10/2015 17:50

Not too bad today my friends. And thanks again for all the heads up from you bam!

This thread would be non-existent without your input!

[bamboo2] 24/10/2015 10:43

maxk, following the arrival of Ian Trenholm as NHSBT ceo, about a year ago, I had hopes for more a more transparent relationship, but this has not yet been the case.

My guess is that the confidential deal they have involves mutually beneficial swaps of tech, research, and material for use in ECM production.

[maxk] 23/10/2015 09:28

Are they getting anywhere with the good ol NHS? No mention from the co in the IR.

[bamboo2] 23/10/2015 09:07

mb, I think management are doing a great job, but I do not have the benefit of having met them.

Management aside, have you viewed any of the clinical results in the latest presentation? Dermapure looks to me like it could become the standard treatment for 'hard to treat' wounds.

[multibagger] 23/10/2015 09:02

I have held TRX in the past and profited from it but lost faith in management after attending the AGM and thereafter - more spin than substance imho and many announcements but no prospect changing revenues so far.

In the biotech and related space, CRX is well positioned and poised for strong growth. I don't hold CRX but researching it at the mo.

Good luck all :)

[bamboo2] 23/10/2015 08:58

Hi Ray, in TRX from an early stage, he has been diluted a number of times, [twice?] and is restoring his percentage.

Look here,



Track records are important in fund management and Alan Miller’s is certainly one to make you stop and think.

He started one of Britain’s first hedge funds in 1997 and had a starring role at Gartmore, Jupiter and New Star. His flagship fund generated 17.5pc returns over nine years...

[rayrac] 23/10/2015 08:50

Where does Miller get that kind of money? Or is he a 'front man'?